- Home
- HQI vs OTLK Comparison
HQI vs OTLK Comparison
Compare HQI & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HQI | OTLK |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.0M | 96.4M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HQI | OTLK |
|---|---|---|
| Price | $8.47 | $2.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.00 | $4.00 |
| AVG Volume (30 Days) | 38.2K | ★ 2.7M |
| Earning Date | 11-06-2025 | 12-24-2025 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 412.84 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $31,691,000.00 | $1,505,322.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.17 | $342.80 |
| P/E Ratio | $14.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $0.79 |
| 52 Week High | $15.75 | $3.39 |
Technical Indicators
Market Signals| Indicator | HQI | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 54.08 |
| Support Level | $7.38 | $1.91 |
| Resistance Level | $8.36 | $2.54 |
| Average True Range (ATR) | 0.58 | 0.20 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 66.46 | 34.92 |
Price Performance
Historical ComparisonAbout HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.